Related references
Note: Only part of the references are listed.GnRH antagonist treatment of malignant adrenocortical tumors
Milena Doroszko et al.
ENDOCRINE-RELATED CANCER (2019)
Hsp70 (HSP70A1A) downregulation enhances the metastatic ability of cancer cells
Panagiota Kasioumi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery
Sabine Schuster et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2018)
Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids
Eszter Lajko et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2018)
Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification
Sabine Schuster et al.
PHARMACEUTICS (2018)
Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Joerg B. Engel et al.
CURRENT DRUG TARGETS (2016)
The gonadotropin-releasing hormone system: perspectives from reproduction to cancer
Arturo Aguilar-Rojas et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice
Bence Kapuvari et al.
INVESTIGATIONAL NEW DRUGS (2016)
Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting
Ildiko Szabo et al.
JOURNAL OF PEPTIDE SCIENCE (2015)
Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation
Chenhong Wang et al.
JOURNAL OF PEPTIDE SCIENCE (2015)
Senescence and apoptosis: dueling or complementary cell fates?
Bennett G. Childs et al.
EMBO REPORTS (2014)
Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)
Guenter Emons et al.
GYNECOLOGIC ONCOLOGY (2014)
The role of senescent cells in ageing
Jan M. van Deursen
NATURE (2014)
Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate
Verena Natalie Schreier et al.
PLOS ONE (2014)
Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
Sumi Park et al.
PLOS ONE (2014)
Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner
Roberta M. Moretti et al.
PLOS ONE (2014)
Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives
Florian Hohla et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
Petra Popovics et al.
ONCOTARGET (2014)
Investigation on chemotactic drug targeting (chemotaxis and adhesion) inducer effect of GnRH-III derivatives in Tetrahymena and human leukemia cell line
Eszter Lajko et al.
JOURNAL OF PEPTIDE SCIENCE (2013)
Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108
Karoly Szepeshazi et al.
ONCOTARGET (2013)
In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice
Marilena Manea et al.
ANTI-CANCER DRUGS (2012)
Potential role of a navigator gene NAV3 in colorectal cancer
E. Carlsson et al.
BRITISH JOURNAL OF CANCER (2012)
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate
Ulrike Leurs et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates
Rozsa Hegedues et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins
Anton Stangelberger et al.
PROSTATE (2012)
In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites
Erika Orban et al.
AMINO ACIDS (2011)
Enhanced Enzymatic Stability and Antitumor Activity of Daunorubicin-GnRH-III Bioconjugates Modified in Position 4
Marilena Manea et al.
BIOCONJUGATE CHEMISTRY (2011)
Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect
Pascal Schlage et al.
JOURNAL OF CONTROLLED RELEASE (2011)
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence
Olga V. Leontieva et al.
AGING-US (2010)
Receptor-mediated tumor targeting based on peptide hormones
Gabor Mezo et al.
EXPERT OPINION ON DRUG DELIVERY (2010)
Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Andrew V. Schally et al.
Current Drug Delivery (2010)
Development of an Oxime Bond Containing Daunorubicin-Gonadotropin-Releasing Hormone-III Conjugate as a Potential Anticancer Drug
Ildiko Szabo et al.
BIOCONJUGATE CHEMISTRY (2009)
GnRH-II Antagonists Induce Apoptosis in Human Endometrial, Ovarian, and Breast Cancer Cells via Activation of Stress-induced MAPKs p38 and JNK and Proapoptotic Protein Bax
Stefanie Fister et al.
CANCER RESEARCH (2009)
Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (Review)
Arturo Aguilar-Rojas et al.
ONCOLOGY REPORTS (2009)
GnRH signaling in intrauterine tissues
Hsien-Ming Wu et al.
REPRODUCTION (2009)
New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Gabor Mezo et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview
Wai-Kin So et al.
FEBS JOURNAL (2008)
Diversity of actions of GnRHs mediated by ligand-induced selective signaling
Robert P. Millar et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2008)
Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs
Magdolna Kovacs et al.
PEPTIDES (2007)
Is IGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells?
Krisztina Heredi-Szabo et al.
JOURNAL OF PEPTIDE SCIENCE (2006)
Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-1I, and their receptors in humans
CK Cheng et al.
ENDOCRINE REVIEWS (2005)
Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth
K Herédi-Szabó et al.
PEPTIDES (2005)
Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A smarter chemotherapy
A Nagy et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Gonadotropin-releasing hormone receptors
RP Millar et al.
ENDOCRINE REVIEWS (2004)
Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell tines independent of multidrug resistance-1 (MDR-1) system
AR Günthert et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2004)
Surface antigens/receptors for targeted cancer treatment: The GnRH receptor/binding site for targeted adenocarcinoma therapy
R Eaveri et al.
CURRENT CANCER DRUG TARGETS (2004)
Multi-factorial role of GnRH-I and GnRH-II in the human ovary
PCK Leung et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2003)
Share Paper
